My research interests lie in immunotherapy of B-cell malignancies. I am particularly interested in ways to improve the generation of effective anti-tumour T-cell immune responses post anti-CD20 monoclonal antibody therapy. My research currently focuses on a number of ways to improve anti-CD20 mAb therapy such as combining therapy with immunomodulatory agents, radiation and manipulation of the tumour microenvironment. We are particularly interested in enhancing the efficacy of the novel type II anti-CD20 mAb obinutuzumab. I am also interested in adoptive cell therapy, in particular gene modified T-cells expressing CD19 specific chimeric antigen receptors.